NCT05706909View on ClinicalTrials.gov

The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head

Active, not recruitingOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

July 31, 2027

Conditions
Avascular NecrosisOsteonecrosis
Interventions
DEVICE

Genex with ABMC

Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

Sponsors

Collaborators (1)

Biocomposites Ltd
All Listed Sponsors
collaborator

Biocomposites Ltd

INDUSTRY

lead

The Cleveland Clinic

OTHER

NCT05706909 - The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head | Biotech Hunter | Biotech Hunter